AssetMark Inc
TBPH icon

AssetMark Inc’s Theravance Biopharma TBPH Stock Holding History

AssetMark Inc’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$867 Hold
51
– – ﹤0.01% 3181
2026
Q1 		$828 Hold
51
– – ﹤0.01% 3077
2025
Q4 		$954 Hold
51
– – ﹤0.01% 2949
2025
Q3 		$745 Hold
51
– – ﹤0.01% 2851
2025
Q2 		$563 Buy
+51
New +$496 ﹤0.01% 2723

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AssetMark Inc's TBPH Position: Q2 2026 in Review

AssetMark Inc held its Theravance Biopharma (TBPH) position steady in Q2 2026 at 51 shares worth $867. The position accounts for ﹤0.01% of the portfolio, ranked #3181.

AssetMark Inc first reported a position in TBPH in Q2 2025 and has held it in 5 quarters since. The position peaked at $954 in Q4 2025. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • AssetMark Inc held 51 shares of Theravance Biopharma worth $867 as of Q2 2026.
  • AssetMark Inc left its Theravance Biopharma share count unchanged in Q2 2026.
  • Theravance Biopharma made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3181 holding.
  • AssetMark Inc first reported a position in Theravance Biopharma in Q2 2025 and has held it in 5 quarters since.
  • AssetMark Inc's Theravance Biopharma position peaked at $954 in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.